undamentalytics Newsletter
Sign in

Biocryst Pharmaceuticals Inc income statement

In fiscal 2025, Biocryst Pharmaceuticals Inc reported revenue of $875m, up 94.1% on the year before, operating income of $341m (a 39.0% margin) and net income of $264m, or $1.21 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue756220261714482625214918157271331451875941
Cost of revenue50—————21—42764121921
Gross profit7062—————2424—4516150264327438856920
Research and development74845749425273616785107123209253217175166198
Selling, general and administrative————67131114303768119159214266349337
General and administrative1012129——————————————
Operating income−14−34−50−34−31−46−39−49−57−94−99−175−178−148−104−3341−313
Interest expense——4555569912155999108997975
Income before tax——————————−109−183−182−244−226−87267−381
Income tax———7917000000230243
Net income−13−34−57−39−30−45−43−55−66−101−109−183−184−247−227−89264−385
Diluted EPS−$0.35−$0.76−$1.26−$0.79−$0.55−$0.68−$0.59−$0.75−$0.78−$0.98−$940.00−$1.09−$1.03−$1.33−$1.18−$0.43$1.21−$1.63
Diluted shares (average)———49m55m67m73m74m84m103m116m167m179m186m192m207m219m237m
EBITDA—−32−49−33−30−46−39−48−57−93−99−174−177−147−102−1342−311

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BBIO vs BCRXBCRX vs KNSABCRX vs IONSBCRX vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biocryst Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biocryst Pharmaceuticals Inc.